Epizyme Inc. (NASDAQ:EPZM) shares rose 5% during mid-day trading on Monday . The stock traded as high as $8.92 and last traded at $8.75, with a volume of 316,076 shares. The stock had previously closed at $8.33.

EPZM has been the topic of several recent research reports. Leerink Swann restated a “buy” rating on shares of Epizyme in a research report on Tuesday, April 19th. Zacks Investment Research lowered shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. Wedbush restated an “outperform” rating and issued a $22.00 price target on shares of Epizyme in a research report on Monday, May 9th. Mizuho decreased their price target on shares of Epizyme from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. Finally, HC Wainwright restated a “buy” rating on shares of Epizyme in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $23.11.

The firm has a 50-day moving average of $9.83 and a 200-day moving average of $10.44. The stock’s market cap is $494.94 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. On average, equities analysts anticipate that Epizyme Inc. will post ($2.19) earnings per share for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the sale, the insider now directly owns 35,538 shares in the company, valued at $368,529.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

An institutional investor recently bought a new position in Epizyme stock. California Public Employees Retirement System acquired a new stake in Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned 0.41% of Epizyme at the end of the most recent reporting period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.